Immutep Discontinues Phase III Lung Cancer Trial, Faces $10M Partner Payment

summarizeSummary

Immutep has discontinued its Phase III TACTI-004 lung cancer trial due to futility and faces a US$10 million payment obligation to its partner, Dr. Reddy's, while initiating cost reduction measures.

check_boxKey Events

• Phase III TACTI-004 Trial Discontinued

  Immutep halted its Phase III TACTI-004 study for first-line non-small cell lung cancer (NSCLC) after an interim futility analysis showed patients in the eftilagimod alfa arm underperformed the control arm. A root cause analysis is ongoing to understand the factors behind this outcome.

• US$10 Million Payment Obligation to Partner

  Following the trial discontinuation, Immutep is obligated to pay US$10 million to its licensing partner, Dr. Reddy's, by June 2026, as stipulated by their license agreement terms.

• Cost Reduction Measures and Cash Runway Update

  The company is implementing cost reduction measures, including headcount reductions, and expects its cash runway to extend into H1 CY2028, factoring in the trial wind-down costs and the payment obligation.

• Mixed Pipeline Progress Reported

  While TACTI-004 is discontinued, other programs show progress, including the Phase I IMP761 for autoimmune disease advancing to multiple ascending dose, and the Phase II EFTISARC-NEO trial meeting its primary objective and receiving FDA orphan drug designation.

auto_awesomeAnalysis

The discontinuation of the Phase III TACTI-004 trial represents a critical setback for Immutep, impacting a key late-stage asset in a major indication. The unexpected underperformance of the eftilagimod alfa arm, contrary to prior study results, introduces significant uncertainty regarding the broader development program for eftilagimod alfa, pending the ongoing root cause analysis. The immediate financial consequence is a US$10 million payment obligation to Dr. Reddy's, which is a substantial outflow for a company of this size. While the company's proactive cost reduction measures and extended cash runway into H1 CY2028 provide some stability, investor focus will remain on the implications of this late-stage clinical failure and the future direction of its lead candidate. Positive updates from earlier-stage programs like IMP761 and EFTISARC-NEO are largely overshadowed by this major clinical development.